Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, today announced that it has executed a 2-year renewable paclitaxel manufacturing and supply agreement with a leading European generic manufacturer. Paclitaxel deliveries to this new client are expected to generate sales of about $1.5 to $2.0 million starting in 2006.
